AIA
EGRX

Affinity Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Affinity Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,917
Closed -$311K – 204
2016
Q4 		$311K Hold
3,917
– – 0.03% 135
2016
Q3 		$274K Buy
+3,917
New +$217K 0.02% 132
2016
Q2 		– Sell
-5,167
Closed -$209K – 176
2016
Q1 		$209K Buy
+5,167
New +$328K 0.02% 152

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Affinity Investment Advisors's EGRX Position: Q1 2017 in Review

Affinity Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 3,917 shares — an estimated $311K sold.

Affinity Investment Advisors first reported a position in EGRX in Q1 2016 and held it in 3 quarters. The position peaked at $311K in Q4 2016. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Affinity Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Affinity Investment Advisors sold 3,917 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $311K.
  • Affinity Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • Affinity Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $311K in Q4 2016.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Affinity Investment Advisors's 13F filing for Q1 2017, filed 4 May 2017.